MedTrace Logo

Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity

NCT05792293 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-04-06

No results posted yet for this study

Summary

This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity

Conditions

  • Doxorubicin Induced Cardiomyopathy

Interventions

DRUG

Atorvastatin 40 Mg Oral Tablet

40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Ahmed L Mohamed, Master · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05792293 on ClinicalTrials.gov